Jane Street Group LLC Has $240,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Jane Street Group LLC trimmed its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 19.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,176 shares of the biotechnology company’s stock after selling 5,507 shares during the period. Jane Street Group LLC owned approximately 0.11% of Enanta Pharmaceuticals worth $240,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Wellington Management Group LLP acquired a new stake in Enanta Pharmaceuticals during the third quarter worth about $360,000. State Street Corp grew its stake in Enanta Pharmaceuticals by 6.4% during the third quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock worth $4,662,000 after buying an additional 27,147 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Enanta Pharmaceuticals in the third quarter worth about $903,000. Erste Asset Management GmbH bought a new position in shares of Enanta Pharmaceuticals in the third quarter worth about $1,243,000. Finally, Walleye Capital LLC lifted its holdings in shares of Enanta Pharmaceuticals by 96.4% in the third quarter. Walleye Capital LLC now owns 43,899 shares of the biotechnology company’s stock worth $455,000 after acquiring an additional 21,550 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the sale, the chief executive officer now owns 801,638 shares in the company, valued at approximately $6,461,202.28. The trade was a 0.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 13.64% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. HC Wainwright dropped their target price on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, December 24th. JMP Securities reissued a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Finally, Robert W. Baird dropped their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Price Performance

ENTA opened at $5.09 on Friday. The company’s 50 day moving average price is $7.86 and its two-hundred day moving average price is $11.00. The firm has a market capitalization of $107.86 million, a price-to-earnings ratio of -0.93 and a beta of 0.49. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.87 and a fifty-two week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The business had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business’s revenue for the quarter was down 22.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.33) EPS. As a group, equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.73 EPS for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.